Related Experiment Video

Updated: Feb 22, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K

Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance

Jing Pan1, Yuanyuan Sun1, Ning Zhang1

  • 1Department of Hematology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China.

Oncology Letters
|September 21, 2017
PubMed

Insights

B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) mRNA expression is elevated in multiple myeloma patients, correlating with disease stage and prognosis. Higher BAFF and APRIL levels indicate a poorer outcome.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
  • B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) are key cytokines involved in B-cell survival and proliferation.
  • Dysregulation of BAFF and APRIL has been implicated in various B-cell malignancies, including multiple myeloma.

Purpose of the Study:

  • To investigate the mRNA expression of BAFF and APRIL in mononuclear cells of multiple myeloma patients.
  • To analyze the correlation between plasma BAFF and APRIL concentrations and tumor burden parameters.
  • To evaluate the potential of BAFF and APRIL expression as prognostic markers in multiple myeloma.

Main Methods:

  • Bone marrow mononuclear cells (BMMCs) and plasma were collected from 60 multiple myeloma patients and 20 healthy controls.
  • Quantitative real-time PCR was used to measure BAFF and APRIL mRNA expression in BMMCs.
  • ELISA was employed to detect BAFF and APRIL protein expression in the KM3 cell line.

Main Results:

  • BAFF and APRIL mRNA expression was significantly higher in multiple myeloma patients (initial treatment, remission, and non-remission groups) compared to controls.
  • APRIL mRNA expression increased with disease stage (Stage III > Stage II).
  • A positive correlation was observed between plasma BAFF and APRIL concentrations in multiple myeloma patients.

Conclusions:

  • Elevated BAFF and APRIL expression is characteristic of multiple myeloma, particularly in the initial treatment and non-remission groups.
  • Increased expression of BAFF and APRIL correlates with advanced disease stage.
  • BAFF and APRIL expression patterns may serve as valuable biomarkers for predicting multiple myeloma prognosis.
Keywords:
B-cell activating factorexpressioninductionligandmultiple myelomaproliferation

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.2K

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K